GCP
CNCE

GSA Capital Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

GSA Capital Partners’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-379,244
Closed -$1.24M – 1929
2021
Q3 		$1.24M Buy
379,244
+98,635
+35% +$346K 0.13% 207
2021
Q2 		$1.18M Buy
280,609
+162,360
+137% +$687K 0.13% 180
2021
Q1 		$590K Buy
118,249
+46,622
+65% +$377K 0.1% 267
2020
Q4 		$905K Buy
71,627
+13,532
+23% +$154K 0.15% 159
2020
Q3 		$570K Buy
58,095
+40,744
+235% +$402K 0.1% 312
2020
Q2 		$173K Buy
+17,351
New +$166K 0.1% 383
2020
Q1 		– Sell
-48,565
Closed -$448K – 1692
2019
Q4 		$448K Buy
48,565
+12,470
+35% +$88.4K 0.05% 730
2019
Q3 		$212K Buy
+36,095
New +$383K 0.03% 1145
2019
Q2 		– Sell
-74,820
Closed -$903K – 1822
2019
Q1 		$903K Sell
74,820
-19,080
-20% -$281K 0.09% 343
2018
Q4 		$1.18M Sell
93,900
-77,600
-45% -$1.07M 0.14% 156
2018
Q3 		$2.54M Buy
171,500
+47,800
+39% +$752K 0.14% 146
2018
Q2 		$2.08M Buy
+123,700
New +$2.4M 0.1% 257
2018
Q1 		– Sell
-69,300
Closed -$1.79M – 1888
2017
Q4 		$1.79M Buy
+69,300
New +$1.4M 0.11% 288
2017
Q2 		– Sell
-20,500
Closed -$350K – 2027
2017
Q1 		$350K Sell
20,500
-35,809
-64% -$429K 0.02% 1298
2016
Q4 		$579K Buy
56,309
+3,204
+6% +$29.3K 0.03% 900
2016
Q3 		$537K Sell
53,105
-97,643
-65% -$1.07M 0.03% 1019
2016
Q2 		$1.69M Buy
150,748
+105,187
+231% +$1.34M 0.09% 316
2016
Q1 		$622K Sell
45,561
-33,080
-42% -$476K 0.04% 853
2015
Q4 		$1.49M Buy
78,641
+7,254
+10% +$158K 0.07% 425
2015
Q3 		$1.34M Buy
+71,387
New +$1.21M 0.07% 457

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's CNCE Position: Q4 2021 in Review

GSA Capital Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2021, closing a stake of 379,244 shares — an estimated $1.24M sold.

GSA Capital Partners first reported a position in CNCE in Q3 2015 and held it in 20 quarters. The position peaked at $2.54M in Q3 2018. 52 funds tracked by Wall St. Rank hold CNCE as of Q4 2021.

  • GSA Capital Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • GSA Capital Partners sold 379,244 Concert Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.24M.
  • GSA Capital Partners first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 20 quarters.
  • GSA Capital Partners's Concert Pharmaceuticals, Inc. position peaked at $2.54M in Q3 2018.
  • 52 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.